Targeting the tumor vascular supply with vascular disrupting agents

about

Targeting the tumor vascular supply with vascular disrupting agents

Item

http://www.wikidata.org/entity/Q35667726

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Targeting the tumor vascular supply with vascular disrupting agents

@ast

Targeting the tumor vascular supply with vascular disrupting agents

@en

type

Item

label

Targeting the tumor vascular supply with vascular disrupting agents

@ast

Targeting the tumor vascular supply with vascular disrupting agents

@en

prefLabel

Targeting the tumor vascular supply with vascular disrupting agents

@ast

Targeting the tumor vascular supply with vascular disrupting agents

@en

P1476

Targeting the tumor vascular supply with vascular disrupting agents

@en

P2093

Ross A Soo

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Differentiation and definition of vascular-targeted therapies.

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

P304

192-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3978/J.ISSN.2072-1439.2010.11.1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221764549

http://www.w3.org/2001/XMLSchema#string

P698

22263044

http://www.w3.org/2001/XMLSchema#string

P932

3256470

http://www.w3.org/2001/XMLSchema#string